Full-Time
Confirmed live in the last 24 hours
Develops medical devices for vascular conditions
$160k - $220kAnnually
Senior, Expert
Company Historically Provides H1B Sponsorship
Alameda, CA, USA
The position is onsite in Alameda, CA.
Penumbra Inc. specializes in creating medical devices aimed at treating neurovascular and peripheral vascular conditions. Their products, such as the Penumbra System and the Indigo System, are designed to assist healthcare professionals in addressing issues like stroke and other vascular diseases. These devices work by providing advanced tools for interventions in neurology and vascular surgery, allowing for effective treatment options. Unlike many competitors, Penumbra focuses specifically on these specialized areas, ensuring their products are tailored to the needs of medical professionals in hospitals and clinics across Europe and the Americas. The company's goal is to continuously innovate and improve their medical devices, enhancing the quality of care provided to patients.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Alameda, California
Founded
2004
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Parental Leave
Paid Vacation
Paid Sick Leave
Paid Holidays
Penumbra launches Access25 delivery microcatheter designed for brain aneurysm access.
Penumbra recently launched the ACCESS25 Delivery Microcatheter, a single lumen medical device designed to aid physicians in accessing the neurovasculature for the delivery of Penumbra's advanced .020" coil platform.
ALAMEDA, Calif., Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the board of directors effective April 1, 2025. Kassing joined Penumbra's Board of Directors in 2008 and has served as Presiding Director since 2015."We are grateful for Don's many contributions to the board over the years, particularly his wisdom and guidance in complex situations and through our phases of growth," said Adam Elsesser, board chair, president and chief executive officer of Penumbra. "We also thank Don for his steadfast leadership and dedication to helping Penumbra advance our mission of helping more and more people over the years."Mr. Kassing is President Emeritus of San Jose State University
Penumbra plans to expand its manufacturing capacity with a new facility in Costa Rica.
ALAMEDA, Calif., Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024. Financial Highlights: Adjusted revenue1 of $321.3 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 12.9% adjusted2 or 13.0% in adjusted constant currency2 compared to the fourth quarter of 2023. Adjusted revenue1 of $1,200.4 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 13.4% in adjusted2 and adjusted constant currency2 compared to the full year 2023